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Abstract
Purpose: Physiological respiratory motion of tumors growing in the lung can be corrected with respiratory gating
when treated with radiotherapy (RT). The optimal respiratory phase for beam-on may be assessed with a
respiratory phase optimizer (RPO), a 4D image processing software developed with this purpose.
Methods and Materials: Fourteen patients with lung cancer were included in the study. Every patient underwent
a 4D-CT providing ten datasets of ten phases of the respiratory cycle (0-100% of the cycle). We defined two
morphological parameters for comparison of 4D-CT images in different respiratory phases: tumor-volume to lung-
volume ratio and tumor-to-spinal cord distance. The RPO automatized the calculations (200 per patient) of these
parameters for each phase of the respiratory cycle allowing to determine the optimal interval for RT.
Results: Lower lobe lung tumors not attached to the diaphragm presented with the largest motion with
breathing. Maximum inspiration was considered the optimal phase for treatment in 4 patients (28.6%). In 7 patients
(50%), however, the RPO showed a most favorable volumetric and spatial configuration in phases other than
maximum inspiration. In 2 cases (14.4%) the RPO showed no benefit from gating. This tool was not conclusive in
only one case.
Conclusions: The RPO software presented in this study can help to determine the optimal respiratory phase for
gated RT based on a few simple morphological parameters. Easy to apply in daily routine, it may be a useful tool
for selecting patients who might benefit from breathing adapted RT.
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Introduction
Lung cancer is the first cause of cancer death in the
world with an overall 5 year survival rate inferior to
15%. It has been shown that local control after radio-
therapy (RT) is dose-dependent with a better overall-
survival for patients with the disease locally controlled
[1-3]. Nevertheless, physiological respiratory motion of
primary lung tumors may challenge the chances of
obtaining an optimal local control rate after RT.
There are presently several approaches under investi-
gation aiming to correct for tumor motion potentially
leading to a better conformality of RT: tumor tracking,
synchronizing the beam-on/beam-off time with respira-
tory motion (gating), or using 4D-CT to determine the
average tumor motion during a respiratory cycle in
order to define an internal target volume [4-7]. A 4D-
CT acquires sets of images in different respiratory
phases and can be employed for respiratory gated radio-
therapy [8]. Systematic errors can thus be reduced and
reliable target margins can be defined, in order to avoid
the risk of underdosing due to tumor motion [9].
Respiratory gating has been shown to reduce the size of
the planning treatment volume (PTV) defined by 4D-CT
and is expected to improve the therapeutic ratio by rais-
ing the dose to the tumor and decreasing the dose to
the surrounding normal tissues [10,11].
Although there are techniques compensating for
respiratory motion during RT and delivering RT during
one specific moment of the respiratory cycle, the opti-
mal moment for delivering RT remains unknown and
controversial. Irradiation during deep inspiratory breath
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advantages in terms of lung sparing through the inspira-
tory expansion of the healthy lung tissue [12,13]. How-
ever, DIBH may not be feasible in patients with
compromised pulmonary function. On the other hand,
end-expiration is considered to be more reliable by
others because it is longer and more reproducible than
end-inspiration [14].
In this report we present a respiratory phase optimizer
(RPO) for breathing adapted RT (BART) in order to
determine the optimal irradiation phase based on a few
simple morphological parameters.
Methods and Materials
Fourteen patients with a primary or recurrent lung can-
cer were retrospectively studied. 4D-CTs were acquired
during 4 to 6 respiratory cycles for every patient in the
s t u d y .P a t i e n td a t as e t sw e r ep r o v i d e db yt h eG e n e v a
University Hospital (6 cases), the CRLC Val d’Aurelle (6
cases), and by the General Electric Corporation (2
cases).
Ten 4D-CT axial images corresponding to ten time
bins (phases) of the respiratory cycle (i.e., in 10% incre-
ments) were reconstructed, using a maximum intensity
projection (MIP) system (Figure 1). The MIP (maximum
intensity projection) is a visualization method for 3 D
imaging data. It was first described by Wallis et al.o r i -
ginally called “maximum activity projection”, for nuclear
medicine use [15]. It is now widely employed in radiol-
ogy and in particular for 4D-CT [16]. During the 4D
image acquisition, the scan extracts information con-
tinuously during a time interval equivalent to a breath-
ing cycle. After that, and using an external physiological
signal, the ADW (advantage workstation) system can
reconstruct retrospectively 10 CT sets, each of them
representing an acquisition on the same breathing
phase. Therefore, our cam gets 10 CT-scans equivalent
to 10 breathhold positions. For the same slice coordi-
nates, 10 different values for the same voxel in the
DICOM reference are obtained. A MIP can be created
by building a new image, looking for the maximum
value of the 10 different scans in the corresponding
voxel. In Geneva, the MIP system was implemented by
a commercial software provided on the Biograph TP 64
scanner (Syngo software, Siemens Medical Solutions,
Erlangen, Germany). A time reference for the 4D image
datasets was obtained with the Real-Time Position Man-
agement system (RPM, Varian Medical Systems Inc.,
Palo Alto, CA) for 8 patients and the Anzai system
(Anzai AZ-733V system, Anzai Medical Co, Ltd., Tokyo,
Japan) for 6 patients.
As shown in Figure 1, two parameters were defined to
compare the images of each phase: a) the target to lung
volume ratio (T/L ratiovol), ideally as small as possible
a n db )t h et u m o rt os p i n a lc o r dd i s t a n c e( T - C dist),
sought to be as large as possible. A low T/L ratiovol may
obviously result in optimal target coverage with a simul-
taneous reduced lung irradiation. DIBH has shown the
potential for a reduced lung V20 (i.e., percent of lung
volume receiving 20 Gy) [12]. Choosing the phase where
T-Cdist is the largest is based on the fact that dose con-
straints to the spinal cord have the highest priority in
ongoing trials [17]. An image processing software ("Myr-
ian
®”, developed by the Intrasense Company, Montpel-
lier, France) was used for delineation and volume
determination of the tumor and OARs (Figure 2). The
external limits of the target and of the OARs were
defined on images derived directly from a DICOM CD
to work with usable cross sections. All the contouring
was done by the same author (NP). The segmentation
of the gross tumor volume (GTV) and of the OARs
(lungs and spinal cord) is done by “Myrian
®” semi-auto-
matically and automatically, respectively. This process
results in the definition of four regions of interest (ROI):
the GTV, the right lung, the left lung and, the spinal
cord.
Because “Myrian
®” i sn o ta b l ei nt h ec u r r e n tv e r s i o n
to calculate T/L ratiovol and T-Cdist,a l lt h e s ed a t aa r e
then transferred to the RPO, where their calculations
and graphical presentation are automatized for each
respiratory phase. In this process, “Myrian
®” is unable
to perform an automatic propagation of TV and OAR
delineated from one phase to the other nine. So, this
sequence is repeated for each of the ten phases of the
respiratory cycle and with the CT data acquired in max-
imal inspiration (the reference). Once the data are col-
lected, the RPO is able to display a bar graph for both
comparison parameters: the T/L ratiovol and the T-Cdist.
A graph displays, in addition, the absolute ipsilateral
lung volume measured at each respiratory phase. A
synoptic summary of the two graphs is presented to the
user who may then proceed to the assessment of the
optimal respiratory phase.
For the present study the percentual difference
between the optimal respiratory phase and maximal
inspiration (the reference) was assessed. If both were
coincident, we computed, in addition, the percentual
difference between the optimal respiratory phase and
the least optimal one. We considered that there was no
gain if the difference was ≤ 20%.
Results
Patients and tumor characteristics are presented in
Table 1. The output of the RPO for each individual case
is presented in additional file 1: RPO_appendice.doc.
Table 2 and Table 3 present, respectively, (T/L ratiovol)
and (T-Cdist) for the 14 patients according to the ten
sequential respiratory phases chosen in our study.
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Page 2 of 8As also shown in Table 2, maximal inspiration
occurred mostly at the beginning of the 4D-CT record-
ing: phase 0-9% in 9 patients and 10-19% in 4 patients.
Only in patient #9 maximal inspiration occurred during
the phase 60-69% of the respiratory cycle. Concerning
the optimal T/L ratiovol, the optimal respiratory phase
coincided with maximal inspiration in only 6 cases. The
mean difference between the optimal respiratory phase
and maximal inspiration (the reference) was 15% (SD ±
19) ranging from 0 (optimal phase coinciding with max-
imal inspiration) to 67%. Compared to the worst phase
of the respiratory cycle, the mean difference between
t h eo p t i m a lp h a s ea n dt h el e s so p t i m a lo n ew a s3 4 %
(SD ± 18) ranging from 12 to 79%.
Regarding the second parameter, the T-Cdist, the opti-
mal phase coincided with maximal inspiration in only 3
cases (Table 3). The mean difference between the opti-
mal respiratory phase and maximal inspiration was 5.5%
Figure 1 Flowchart of the process.
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Page 3 of 8Figure 2 Visualization of all the “ROI” necessary to calculate the criteria of comparison.
Table 1 Patients and tumor characteristics
Patient Age Sex Site Stage Histology Mean GTV volume (cm
3)
1 unknown M Right middle lobe T2N0M0 unknown 90
2 unknown F Left lower lobe TXN2M0 unknown 403
3 46 M Right paratracheal TXN3M0 SCC 27
4 51 M Right upper lobe T2N2M0 NSCLC 86
5 75 F Right lower lobe T1N0M0 AC 2
6 75 F Right lower lobe T1N0M0 AC 2
7 71 M Right upper lobe T1N0M0 unknown 7
8 64 F Right upper lobe T1N0M0 AC 10
9 62 M Left lower lobe T3N0M0 unknown 2
10 81 F Left lower lobe T2N1M0 SCC 68
11 65 M Left upper lobe Stage IV (M1) SCC 37
12 81 M Right middle lobe T2N1M0 SCC 66
13 70 M Right upper lobe T1N0M0 AC 6
14 63 F Right lower lobe Extensive. disease SCLC 10
Table 1: SCC = squamous cell carcinoma, NSCLC = non-small cell lung cancer, AC = adenocarcinoma, SCLC = small cell lung cancer.
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Page 4 of 8(SD ± 7.0) ranging from 0 to 27%. Compared to the
worst phase of the respiratory cycle, the mean difference
between the optimal phase and the less optimal one was
10% (SD ± 11) ranging from 2 to 46%.
With a cut-off of 20% only 2 cases showed no benefit
in either of both parameters (patients #7 and #10). In 11
patients, however, a substantial gain was observed for
the T/L ratiovol, the optimal phase coinciding with maxi-
mal inspiration in 4 (28.6%) and differing from maximal
inspiration in 7 (50%). In only one patient (7%) (Patient
#4) maximal inspiration was optimal for the T/L ratiovol,
but was suboptimal for the T-Cdist Figure 3 displays the
corresponding overall summary.
Discussion
Physiological respiratory motion is a major challenge for
lung cancer RT. The range of motion can reach an aver-
age up to 12 ± 6 mm for tumors in the lower lung lobes
[18]. Giraud et al., observed large diaphragm displace-
ments in the cranio-caudal direction during free
Table 2 Tumor to lung volume parameter (T/L ratiovol = 100* Tumor volume/Ipsilateral lung volume)
Patient Respiratory phase Phase opt =
ref
% gain opt/
ref
% gain opt/
worst
0-
9%
10-
19%
20-
29%
30-
39%
40-
49%
50-
59%
60-
69%
70-
79%
80-
89%
90-
99%
1 1.90 2.00 1.60 2.00 1.90 1.90 2.20 2.00 1.90 1.90 no 20 27
2 33.5 35.8 44.7 56.6 65.5 71.7 71.1 59.0 45.8 37.6 yes 0 53
3 1.20 1.10 1.20 1.00 1.20 1.30 1.20 1.30 1.20 1.20 no 17 23
4 5.10 6.00 5.90 6.00 6.70 6.40 6.40 6.6 6.00 5.50 yes 0 24
5 0.09 0.06 0.08 0.13 0.14 0.15 0.12 0.08 0.07 0.13 no 33 60
6 0.12 0.04 0.11 0.16 0.14 0.19 0.12 0.10 0.09 0.17 yes 67 79
7 0.25 0.23 0.22 0.22 0.22 0.23 0.24 0.24 0.24 0.24 no 12 12
8 0.30 0.30 0.36 0.41 0.44 0.43 0.42 0.44 0.42 0.31 yes 0 32
9 0.11 0.11 0.09 0.09 0.09 0.11 0.12 0.12 0.12 0.12 no 0 25
10 5.50 5.60 5.80 5.90 5.90 6.70 6.30 5.90 5.70 6.10 yes 0 18
11 2.75 2.15 1.76 1.86 1.53 1.90 2.15 1.95 2.18 2.64 no 29 44
12 5.50 5.70 5.20 5.60 4.70 3.80 4.50 4.70 4.80 5.30 no 31 33
13 0.26 0.26 0.26 0.27 0.25 0.32 0.32 0.32 0.31 0.26 no 4 22
14 0.40 0.42 0.47 0.48 0.40 0.44 0.52 0.44 0.40 0.40 yes 0 23
Phase where maximal inspiration was observed is indicated by underlining
Ref = maximal inspiration, opt = optimal phase found by RPO, worst = worst phase found by RPO
Table 3 Tumor to spinal cord distance parameter (T-Cdist) in mm.
Patient Respiratory phase Phase opt =
ref
% gain opt/
ref
% gain opt/
worst
0-
9%
10-
19%
20-
29%
30-
39%
40-
49%
50-
59%
60-
69%
70-
79%
80-
89%
90-
99%
1 165 164 163 167 170 167 168 166 165 164 no 4 4
2 66 67 66 68 69 68 67 69 66 67 no 5 5
3 63 61 57 60 60 58 61 60 58 58 yes 0 11
4 75 91 95 91 65 70 70 72 79 74 no 27 46
5 43 41 42 41 41 40 40 38 37 40 yes 0 16
6 40 43 41 41 44 43 39 41 40 42 no 10 13
7 115 115 114 115 115 114 116 113 115 115 no 1 3
8 126 129 129 128 127 128 128 126 126 127 no 2 2
9 72 72 72 71 72 70 71 72 71 71 no 0 3
10 47 50 50 48 47 47 51 51 49 49 no 9 9
11 74 70 72 70 70 71 73 72 70 71 no 6 6
12 61 60 58 61 63 61 64 63 64 68 no 11 17
13 83 84 84 84 84 84 84 84 85 84 no 2 2
14 92 90 89 88 89 90 90 90 88 88 yes 0 5
Phase where maximal inspiration was observed is indicated by underlining
Ref = maximal inspiration, opt = optimal phase found by RPO, worst = worst phase found by RPO
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Page 5 of 8breathing with an average range of 34 mm and a maxi-
mum of 67 mm between inspiration and expiration.
Reduced motion, however, has been reported for tumors
in the lung apices with an average of 8 mm displace-
ment in the cranio-caudal direction between inspiration
and expiration [19]. A patient’s breathing pattern varies
from day to day (inter-fraction motion) and can vary
during an individual RT fraction (intra-fraction motion)
[20]. As a consequence of respiratory motion, planning
target volume (PTV) margins in the order of 1.5-2 cm
are commonly used for RT without breathing control.
These margins increase, obviously, the irradiated lung
volume and consequently the risk of pulmonary radia-
tion toxicity [21]. The most consistent and predictive
parameters for radiation induced lung toxicity are the
V20 and the mean lung dose (MLD) [22,23]. It is widely
accepted that keeping V20 <30-37% and MLD <20Gy
may yield a relatively low risk of pneumonitis (<20%).
Our findings are consistent with Giraud et al., in his
analysis of intrathoracic organ motion during breathing
Patient number
2 (14.4%)
No difference in terms of morphological criteria
No interest of Gating
7 (50%)
Other phase than reference found to be optimal
with gain compared to reference
Gating interest in an optimal phase other than maximal inspiration
4 (28.6%)
Reference phase (max. inspiration) found to be optimal
with gain compared to worst respiratory phase
Gating interest in maximal inspiration
1 (7%)
Reference phase found to be optimal for T/L ratiovol
Other phase than ref. found to be optimal for T-Cdist
Gating interest in optimal or reference phase (need for DVH analysis)
Figure 3 Overview of morphological results and their interpretation.
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and not attached to the diaphragm (i.e., patients #2, #5,
#6, #9, #10, and #14) presented with large variation of
T/L ratiovol or T-Cdist., translating in a potential benefit
from respiratory gating techniques. Giraud et al.,
observed also that the smallest displacements were in
the apices and near the tracheal carina. This is in agree-
ment with our observation that centrally located tumors
may benefit less from gating based on the present algo-
rithm, especially when fibrous attachments to the med-
iastinum restrict their mobility (e.g., patient #3). Five
tumors growing in the superior lung regions (i.e.,
patients #4, #7, #8, #11, and #13) presented less, though
not negligible, changes in the chosen comparative para-
meters. For patients with tumors growing in the poster-
ior mediastinum, close to the spinal cord, the RPO
helped to find the optimal respiratory phase other than
maximal inspiration (i.e., patient #4). Maximum inspira-
tion, the reference, was optimal in only 28.6% of cases
(Figure 3). In 50%, however, other phases of the respira-
tory cycle were found to be optimal as identified by
RPO.
Although, gating techniques are reasonably time con-
suming, and they may not be needed for every patient.
A threshold of tumor motion or tumor volume needs to
be defined above which gating can be recommended.
Starkschall et al., found that patients with small tumors
(GTV <100 cm3) benefitted the most from gating [24].
Therefore, the RPO software may also help to identify
patients with minimal tumor motion influence for
whom a gating-free treatment can be recommended.
Easy to apply in daily routine, fast in getting the opti-
mization result, and no special hardware needed are the
main practical advantages of the RPO worth to be high-
lighted. It is important, however, to plan on a 4D-CT to
be able to acquire synchronized image sets. Data analy-
sis represents about 2000 calculations (volumes, densi-
ties, surfaces, inertia axes, density histograms, ratio of
volumes, and distances) for every patient.
Variability in target volume delineation is a major
source of error in 4D-CT treatment planning. Because
all the contours were defined by the same author, inter-
observer variability was unavailable in our study in
response to the need of technique novelties claimed in
some recent literature in the 4D-CT era [25]. In a new
version of the Myrian software, a contour propagation
tool has been integrated which is expected to reduce
intra-observer variability, but the accuracy of this tool
needs to be investigated in a dedicated study before
implementation in clinical routine.
An evident limitation of our study is the reduced
number of patients studied so far and the restricted mor-
phological parameters of the comparison not including
dose-volume parameters in the analysis. Nevertheless,
it seems reasonable to assume a dosimetric gain when
treating patients in the optimal respiratory phase selected
by the RPO.
Further development of the presented software is
planned in order to adapt it for tumor locations in the
upper abdomen as treatment reproducibility may also be
conditioned by respiratory motion. In addition, the den-
sity histograms obtained with “Myrian
®” may also be
used to assess the treatment response after treatment.
Conclusion
The RPO software presented in this study can help to
determine the optimal respiratory phase for gated RT
based on a few simple morphological parameters. Easy
t oa p p l yi nd a i l yr o u t i n e ,i tm a yb eau s e f u lt o o lf o r
selecting patients who might benefit from BART.
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